Sean Nolan

Sean P.
Nolan currently works at Taysha Gene Therapies, Inc., as Chairman & Chief Executive Officer from 2022, Nolan Capital LLC, as Chairman & President from 2019, Istari Oncology, Inc., as Chairman from 2018, Encoded Therapeutics, Inc., as Chairman from 2018, Affinia Therapeutics, Inc., as Chairman from 2019, Jaguar Gene Therapy LLC, as Executive Chairman from 2021, Ventas, Inc., as Independent Director from 2019, and John Carroll University, as Director.
Mr. Nolan also formerly worked at Novartis Gene Therapies, Inc., as President, Chief Executive Officer & Director from 2015 to 2018, Aquinox Pharmaceuticals, Inc., as Independent Director from 2015 to 2019, Neoleukin Therapeutics, Inc., as Director, Neoleukin Therapeutics, Inc., as Independent Director from 2015 to 2020, Social Capital Suvretta Holdings Corp.
II, as Independent Director from 2021 to 2023, Abbott Laboratories, as Principal, InterMune, Inc., as Chief Business Officer & Executive Vice President from 2013 to 2015, Reata Pharmaceuticals, Inc., as Chief Commercial Officer from 2011 to 2012, OVATION Pharmaceuticals, Inc., as Vice President-Marketing & Sales Operations from 2004 to 2009, and Lundbeck, Inc., as President & Chief Commercial Officer from 2009 to 2010.
Mr. Nolan received his undergraduate degree from John Carroll University.